POLD4
ENSG00000175482
Target class
Enzyme
Chromosome
11
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- POLD4
- Gene name
- DNA polymerase delta 4, accessory subunit
- Gene symbol
- POLD4
- Protein name
- DNA polymerase delta subunit 4 (DNA polymerase delta subunit p12)
- p12
- POLDS
- Gene biotype
- Protein coding
- Gene family
- DNA polymerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 149.52
- Tissue specificity (Gini)
- 0.298
- Tissue specificity (tau)
- 0.635
- KEGG gene identifiers
- hsa:57804
- Protein interaction confidence
- 0.863
- Protein interaction partners
- 11
- R-HSA-110314
- R-HSA-174411
- R-HSA-174414
- R-HSA-174417
- R-HSA-174437
- R-HSA-5358565
- R-HSA-5358606
- R-HSA-5651801
- R-HSA-5656169
- R-HSA-5685942
- R-HSA-5696397
- R-HSA-5696400
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-69091
- R-HSA-69166
- R-HSA-69183
- End position
- 67356972
- Start position
- 67350772
- Chromosome
- 11
- Strand
- Reverse
- Nucleus . Note=Partially recruited to DNA damage sites within 2 hours following UV irradiation, before degradation. .
- Centriolar satellite
Publication evidence
- PubMed 22801543
- Tissue specificity (tau)
- 0.635469
- Expression inequality (Gini)
- 0.298168
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 149.52
- Artery - Aorta
- 109.18
- Spleen
- 105.62
- Small Intestine - Terminal Ileum
- 102.81
- Artery - Tibial
- 102.35
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes149.52
- Artery - Aorta109.18
- Spleen105.62
- Small Intestine - Terminal Ileum102.81
- Artery - Tibial102.35
- Artery - Coronary101.14
- Cells - Cultured fibroblasts92.98
- Prostate92.21
- Liver91.53
- Esophagus - Mucosa80.98
- Bladder78.73
- Lung77.26
- Colon - Transverse74.56
- Nerve - Tibial74.46
- Whole Blood72.12
- Vagina70.94
- Adipose - Subcutaneous66.37
- Cervix - Endocervix66.24
- Adipose - Visceral (Omentum)65.33
- Cervix - Ectocervix63.79
- Thyroid62.4
- Uterus60.17
- Esophagus - Muscularis58.95
- Stomach57.88
- Esophagus - Gastroesophageal Junction57.73
And 29 more, listed on the interactive page.
Biological processes
- GO:0006261
- GO:0005634
- GO:0005654
Molecular functions
- GO:0005515
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor